PMID- 17536745
OWN - NLM
STAT- MEDLINE
DCOM- 20070628
LR  - 20191210
IS  - 0146-4760 (Print)
IS  - 0146-4760 (Linking)
VI  - 31
IP  - 2
DP  - 2007 Mar
TI  - Evaluation of a rapid oral fluid point-of-care test for MDMA.
PG  - 98-104
AB  - Cozart Bioscience Limited has developed novel lateral flow technology that allows 
      the detection of drugs of abuse in biological fluids and suspect powders. This 
      paper describes the application of this technology for the detection of 
      3,4-methylenedioxymethamphetamine (MDMA) in oral fluid. Samples (N = 370) were 
      obtained from the analytical laboratory at Cozart Bioscience Limited following 
      their routine analysis for drugs of abuse. Oral fluid samples were screened for 
      the presence of MDMA and methamphetamine using the Cozart RapiScan System (CRS) 
      and then confirmed for the presence of amphetamines (amphetamine, 
      methamphetamine, MDA, MDMA, MDEA, and MBDB) by gas chromatography-mass 
      spectrometry (GC-MS). In addition to the detection of MDMA and methamphetamine, 
      the CRS cross-reacts with high levels of amphetamine to give a positive result. 
      One hundred and twenty-one samples screened positive using the CRS. Six of these 
      samples were confirmed negative for MDMA and methamphetamine, but contained very 
      high levels of amphetamine. Employing a screening cutoff of 45 ng/mL for the CRS 
      and a confirmation cutoff of 30 ng/mL for GC-MS, the sensitivity, specificity, 
      and accuracy were 96.6, 96.8, and 96.8%, respectively. When applying the 
      Substance Abuse and Mental Health Services Administration recommended 
      confirmation cutoff for amphetamines of 50 ng/mL, the sensitivity, specificity, 
      and accuracy increased marginally to 98.3, 96.9, and 97.3%, respectively.
FAU - Wilson, Lisa
AU  - Wilson L
AD  - Cozart Bioscience Limited, Abingdon, Oxfordshire OX14 4RY, United Kingdom.
FAU - Jehanli, Ahmed
AU  - Jehanli A
FAU - Hand, Chris
AU  - Hand C
FAU - Cooper, Gail
AU  - Cooper G
FAU - Smith, Robert
AU  - Smith R
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - J Anal Toxicol
JT  - Journal of analytical toxicology
JID - 7705085
RN  - 0 (Hallucinogens)
RN  - 44RAL3456C (Methamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Gas Chromatography-Mass Spectrometry
MH  - Hallucinogens/*analysis
MH  - Methamphetamine/analysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*analysis
MH  - *Point-of-Care Systems
MH  - Reproducibility of Results
MH  - Saliva/*chemistry
MH  - Sensitivity and Specificity
MH  - Substance Abuse Detection/*methods
EDAT- 2007/06/01 09:00
MHDA- 2007/06/29 09:00
CRDT- 2007/06/01 09:00
PHST- 2007/06/01 09:00 [pubmed]
PHST- 2007/06/29 09:00 [medline]
PHST- 2007/06/01 09:00 [entrez]
AID - 10.1093/jat/31.2.98 [doi]
PST - ppublish
SO  - J Anal Toxicol. 2007 Mar;31(2):98-104. doi: 10.1093/jat/31.2.98.